Values First Advisors Inc. Takes $84,000 Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

Values First Advisors Inc. bought a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 1,644 shares of the company’s stock, valued at approximately $84,000.

A number of other institutional investors have also recently added to or reduced their stakes in CRNX. AQR Capital Management LLC lifted its holdings in Crinetics Pharmaceuticals by 3.3% during the second quarter. AQR Capital Management LLC now owns 7,126 shares of the company’s stock valued at $319,000 after purchasing an additional 227 shares in the last quarter. Amalgamated Bank lifted its stake in Crinetics Pharmaceuticals by 20.8% in the 2nd quarter. Amalgamated Bank now owns 2,692 shares of the company’s stock valued at $121,000 after buying an additional 464 shares in the last quarter. Comerica Bank purchased a new position in Crinetics Pharmaceuticals in the 1st quarter valued at about $33,000. Hennion & Walsh Asset Management Inc. boosted its holdings in Crinetics Pharmaceuticals by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 38,087 shares of the company’s stock worth $1,783,000 after buying an additional 927 shares during the last quarter. Finally, Quest Partners LLC purchased a new stake in Crinetics Pharmaceuticals during the 2nd quarter worth approximately $42,000. Institutional investors and hedge funds own 98.51% of the company’s stock.

Crinetics Pharmaceuticals Trading Down 1.3 %

Crinetics Pharmaceuticals stock opened at $57.96 on Friday. The stock has a market cap of $4.57 billion, a P/E ratio of -15.33 and a beta of 0.63. The company has a 50-day moving average price of $53.49 and a 200 day moving average price of $49.79. Crinetics Pharmaceuticals, Inc. has a 12-month low of $25.75 and a 12-month high of $60.04.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last posted its earnings results on Thursday, August 8th. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.08). The business had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.47 million. The firm’s revenue for the quarter was down 59.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.94) EPS. As a group, analysts forecast that Crinetics Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. raised their target price on Crinetics Pharmaceuticals from $47.00 to $54.00 and gave the company an “overweight” rating in a research report on Tuesday, July 9th. HC Wainwright raised their price objective on Crinetics Pharmaceuticals from $60.00 to $69.00 and gave the company a “buy” rating in a report on Friday, August 9th. Piper Sandler reaffirmed an “overweight” rating and set a $97.00 target price on shares of Crinetics Pharmaceuticals in a report on Tuesday, July 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $90.00 price target on shares of Crinetics Pharmaceuticals in a research note on Monday, September 16th. Finally, JMP Securities restated a “market outperform” rating and set a $80.00 price target on shares of Crinetics Pharmaceuticals in a research report on Friday, September 27th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $68.55.

Insider Activity at Crinetics Pharmaceuticals

In other Crinetics Pharmaceuticals news, insider Stephen F. Betz sold 1,035 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $51.50, for a total transaction of $53,302.50. Following the completion of the transaction, the insider now owns 68,576 shares of the company’s stock, valued at $3,531,664. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, insider Stephen F. Betz sold 3,000 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $53.19, for a total value of $159,570.00. Following the sale, the insider now owns 69,611 shares in the company, valued at approximately $3,702,609.09. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Stephen F. Betz sold 1,035 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $51.50, for a total value of $53,302.50. Following the transaction, the insider now directly owns 68,576 shares in the company, valued at approximately $3,531,664. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 43,410 shares of company stock worth $2,275,929. Company insiders own 6.00% of the company’s stock.

Crinetics Pharmaceuticals Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.